Actinium Pharmaceuticals
ATNM
36 hedge funds and large institutions have $8.22M invested in Actinium Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
29% more capital invested
Capital invested by funds: $6.39M → $8.22M (+$1.83M)
29% more funds holding
Funds holding: 28 → 36 (+8)
0.28% more ownership
Funds ownership: 0.4% → 0.68% (+0.28%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.33M |
| 2 |
DAM
DLD Asset Management
New York
|
+$2.01M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.13M |
| 4 |
AC
Armistice Capital
New York
|
+$927K |
| 5 |
SCM
Sio Capital Management
New York
|
+$610K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$89.9K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$56.1K |
| 3 |
VF
Virtu Financial
New York
|
-$46.7K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$26K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| $6K | -$46.7K | -2,750 | -84% |
|
27
Morgan Stanley
New York
| $6K | -$4.81K | -283 | -34% |
|
|
RJFSA
28
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $6K | -$4.54K | -267 | -32% |
|
|
HFM
29
Hartford Financial Management
Hartford,
Connecticut
| $6K | – | – | – |
|
30
Ameriprise
Minneapolis,
Minnesota
| $5K | +$8.5K | +500 | New |
|
31
State Street
Boston,
Massachusetts
| $4K | – | – | – |
|
|
BEAM
32
Baker Ellis Asset Management
Vancouver,
Washington
| $4K | +$5.66K | +333 | New |
|
|
33
UBS Group
Zurich,
Switzerland
| $1K | -$89.9K | -5,289 | -98% |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$17 | -1 | -1% |
|
35
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$1.92K | +113 | New |
|
|
ARTA
36
A.R.T. Advisors
New York
| – | -$26K | -1,314 | Closed |
|
|
TSS
37
Two Sigma Securities
New York
| – | -$14K | -692 | Closed |
|
38
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -423 | Closed |
|
|
SXL
39
Summit X LLC
Chesterfield,
Missouri
| – | -$8K | -367 | Closed |
|
|
AG
40
Advisor Group
Phoenix,
Arizona
| – | -$3K | -133 | Closed |
|
ATNM Hedge Fund Activity: Q1 2018 in Review
36 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2018, worth a combined $8.22M — up 29% from $6.39M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATNM positions and 6 closed out — a net gain of 8 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.33M. The largest seller was UBS Group, cutting an estimated $89.9K.
- 36 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2018, up from 28 in Q4 2017.
- Funds reported $8.22M of Actinium Pharmaceuticals stock for Q1 2018, up 29% quarter-over-quarter.
- 14 funds opened new Actinium Pharmaceuticals positions in Q1 2018 and 6 closed out, a net change of +8 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2018 was Anson Funds Management, an estimated $2.33M added.
- The largest Actinium Pharmaceuticals seller in Q1 2018 was UBS Group, an estimated $89.9K sold.
Based on aggregated 13F filings for Q1 2018.